Cargando…

Patiromer utilization in patients with advanced chronic kidney disease under nephrology care in Germany

BACKGROUND: Hyperkalemia (HK) is a frequent condition in patients with chronic kidney disease (CKD) that is associated with high morbidity and mortality. Patiromer has recently been introduced as a potassium binder. Data on patiromer use in patients with CKD in the real-world setting in Europe are l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pecoits-Filho, Roberto, McCullough, Keith, Muenz, Daniel, Quinn, Carol Moreno, Budden, Jeff, Golden, John, de Arellano, Antonio Ramirez, Tillmann, Frank-Peter, Duttlinger, Johannes, Calice-Silva, Viviane, Massy, Ziad A, Bieber, Brian, Robinson, Bruce M, Fliser, Danilo, Reichel, Helmut
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871846/ https://www.ncbi.nlm.nih.gov/pubmed/36726438 http://dx.doi.org/10.1093/ckj/sfac209

Ejemplares similares

International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations?
por: Calice-Silva, Viviane, et al.
Publicado: (2023)

Adherence to the Kidney Disease: Improving Global Outcomes CKD Guideline in Nephrology Practice Across Countries
por: Stengel, Bénédicte, et al.
Publicado: (2020)

Prescription of Direct Oral Anticoagulants to Patients With Moderate-to-Advanced CKD: Too Little or Just Right?
por: Liabeuf, Sophie, et al.
Publicado: (2021)

Chronic kidney disease progression and mortality risk profiles in Germany: results from the Chronic Kidney Disease Outcomes and Practice Patterns Study
por: Reichel, Helmut, et al.
Publicado: (2020)

Potential Surrogate Outcomes for Kidney Failure in Advanced CKD: Evaluation of Power and Predictive Ability in CKDopps
por: Zee, Jarcy, et al.
Publicado: (2021)

Timely Referral to Outpatient Nephrology Care Slows Progression and Reduces Treatment Costs of Chronic Kidney Diseases
por: Lonnemann, Gerhard, et al.
Publicado: (2016)

Prescription of renin‐angiotensin‐aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care
por: Pecoits‐Filho, Roberto, et al.
Publicado: (2019)

Patiromer sorbitex calcium for hyperkalaemia
Publicado: (2019)

The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland
por: Ward, Thomas, et al.
Publicado: (2022)

Case report: Patiromer-induced hypercalcemia
por: Wiederkehr, Michael R., et al.
Publicado: (2019)

Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe
por: Massy, Ziad A, et al.
Publicado: (2019)

Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe
por: Massy, Ziad A, et al.
Publicado: (2019)

A Rare Case of Patiromer Induced Hypercalcemia
por: Kanduri, Swetha Rani, et al.
Publicado: (2021)

What should European nephrology do with the new CKD-EPI equation?
por: Gansevoort, Ron T, et al.
Publicado: (2022)

Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers
por: Lesko, Lawrence J., et al.
Publicado: (2017)

Patiromer Acetate Induced Hypercalcemia: An Unreported Adverse Effect
por: Bhattarai, Shreeyukta, et al.
Publicado: (2019)

Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
por: Desai, Nihar R., et al.
Publicado: (2019)

Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting
por: Di Palo, Katherine E., et al.
Publicado: (2022)

Letter to the editor regarding ‘‘Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-analysis: Patiromer and Sodium Zirconium Cyclosilicate in Hyperkalemia’
por: Zarzuela, Donna, et al.
Publicado: (2021)

Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): design of a multicentre, randomised, double-blind, placebo-controlled, parallel-group study
por: Rafique, Zubaid, et al.
Publicado: (2023)

The association between longer haemodialysis treatment times and hospitalization and mortality after the two-day break in individuals receiving three times a week haemodialysis
por: Fotheringham, James, et al.
Publicado: (2019)

Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients
por: Kovesdy, Csaba P., et al.
Publicado: (2018)

Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors
por: Kloner, Robert A., et al.
Publicado: (2018)

Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
por: Rosano, Giuseppe M C, et al.
Publicado: (2019)

Largest Experience of Safety and Efficacy of Patiromer in Solid Organ Transplant
por: Schnelle, Kendra, et al.
Publicado: (2020)

Challenges and Opportunities of a Virtual Nephrology Meeting: The ISN World Congress of Nephrology 2021
por: Claure-Del Granado, Rolando, et al.
Publicado: (2021)

Point-of-Care Capillary Blood Creatinine: A Prospective study in Cardiology and Nephrology Outpatients
por: Vilaine, Eve, et al.
Publicado: (2021)

Beta-2 microglobulin and all-cause mortality in the era of high-flux hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study
por: Kanda, Eiichiro, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
por: Bounthavong, Mark, et al.
Publicado: (2018)

Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics
por: Weir, Matthew R., et al.
Publicado: (2017)

Management of hyperkalaemia in acute kidney injury in a heart failure patient with patiromer
por: Slawik, Jonathan, et al.
Publicado: (2020)

Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia
por: Colbert, Gates, et al.
Publicado: (2022)

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial( )
por: Butler, Javed, et al.
Publicado: (2022)

A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure
por: Ward, Thomas, et al.
Publicado: (2023)

Routinely measured cardiac troponin I and N‐terminal pro‐B‐type natriuretic peptide as predictors of mortality in haemodialysis patients
por: Eriguchi, Masahiro, et al.
Publicado: (2022)

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia
por: Bushinsky, David A, et al.
Publicado: (2015)

Gut Microbiota and Host Cometabolism Are Altered by Patiromer-Induced Changes in Serum and Stool Potassium
por: Gao, Bei, et al.
Publicado: (2020)

The Role of Patiromer in Delaying the Onset of Renal Replacement Therapy in Patients with Advanced Renal Failure
por: Wadhwa, Nand K., et al.
Publicado: (2021)

Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis
por: Shrestha, Dhan Bahadur, et al.
Publicado: (2021)

Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life
por: Esteban‐Fernández, Alberto, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p5q1h3bjpa086h7gjpro4lpkud